

Supplementary Table 1. Baseline characteristics according to antiplatelet treatment before and after IPTW

Characteristic	Before IPTW				After IPTW			
	Antiplatelet (n=130)	OACs (n=353)	Std diff	P	Antiplatelet (n=479)	OACs (n=483)	Std diff	P
Demographics								
Age in years	73.7±9.9	73.1±8.9	0.067	0.506	73.2±10.4	73.3±8.9	0.005	0.939
Male sex	66 (50.8)	168 (47.6)	0.063	0.605	235 (49.2)	233 (468)	0.018	0.825
Comorbidities								
Hypertension	92 (70.8)	234 (66.3)	0.096	0.411	326 (68.1)	326 (67.5)	0.015	0.906
Diabetes mellitus	42 (32.3)	75 (21.2)	0.251	0.017	116 (24.3)	116 (24.0)	0.005	0.988
Dyslipidemia	51 (39.2)	143 (40.5)	0.026	0.881	182 (38.1)	193 (40.0)	0.038	0.595
Current smoking	17 (13.1)	49 (13.9)	0.023	0.937	72 (15.1)	66 (13.7)	0.042	0.599
Coronary heart disease	11 (8.5)	22 (6.2)	0.085	0.511	29 (6.1)	32 (6.6)	0.020	0.817
Prior stroke or TIA	40 (30.8)	109 (30.9)	0.002	1.000	141 (29.5)	148 (30.6)	0.024	0.752
Laboratory values								
Total cholesterol (mg/dL)	161.3±39.7	163.3±39.5	0.050	0.625	163.6±40.3	162.9±38.7	0.017	0.787
LDL-C (mg/dL)	100.7±34.6	104.0±33.5	0.097	0.342	103.1±35.6	103.1±32.9	0.001	0.992
Triglyceride (mg/dL)	88.7±47.9	89.3±47.6	0.014	0.890	87.8±47.8	89.2±47.6	0.028	0.660
HDL-C (mg/dL)	45.5 ±12.6	45.1 ± 0.7	0.039	0.701	45.3±12.4	45.2±11.8	0.014	0.822
Glycated hemoglobin (%)	6.0±0.9	6.0±1.3	0.020	0.834	6.0±0.9	6.0±1.3	0.018	0.779
Fasting blood sugar (mg/dL)	127.8±45.7	124.4±56.8	0.065	0.507	125.3±43.2	125.4±55.8	0.003	0.960
Aspartate transaminase (IU/L)	27.5±12.2	28.1±11.8	0.053	0.601	28.1±13.1	27.8±11.4	0.026	0.680
Alanine transaminase (IU/L)	18.7±9.8	20.1±11.2	0.137	0.168	19.0±9.8	19.7±10.9	0.067	0.302
eGFR (mL/min/1.73 m ²)*	90.2±41.9	92.3±49.7	0.046	0.643	92.7±44.0	92.0±50.7	0.016	0.806
Baseline scores								
Initial NIHSS	10 (3–15)	9 (2–13)	0.155	0.110	10 (3–14)	9 (3–13)	0.037	0.570
Previous mRS	0 (0–3)	0 (0–2)	0.119	0.391	0 (0–3)	0 (0–2)	0.033	0.605
CHA ₂ DS ₂ -VASc score	5 (4–6)	5 (4–6)	0.122	0.182	5 (4–6)	5 (4–6)	0.002	0.978
HAS-BLED score	3 (2–3)	3 (2–3)	0.075	0.292	3 (2–3)	3 (2–3)	0.003	0.958
Acute treatment								
Intravenous alteplase	38 (29.2)	100 (28.3)	0.020	0.935	141 (29.4)	138 (28.6)	0.017	0.822
Mechanical thrombectomy	25 (19.2)	52 (14.7)	0.120	0.290	81 (16.9)	76 (15.8)	0.029	0.695
Statin	64 (49.2)	195 (55.2)	0.120	0.284	261 (54.6)	261 (54.0)	0.011	0.912
Cerebral artery status								
Severe stenosis	19 (14.6)	26 (7.4)	0.233	0.024	43 (9.0)	44 (9.1)	0.003	1.000
Any cerebral atherosclerosis	105 (80.8)	252 (71.4)	0.220	0.049	358 (74.7)	357 (73.9)	0.020	0.826
CMB status								
CMB burden	2 (1–3)	2 (1–3)	0.005	0.963	2 (1–3)	2 (1–3)	0.017	0.789
Lobar CMB	81 (62.3)	194 (55.0)	0.149	0.179	271 (56.6)	275 (56.9)	0.006	0.962

Values are presented as mean±standard deviation, number (%), of median (interquartile range).

IPTW, inverse probability of treatment weighting; OAC, oral anticoagulant; Std diff, standardized difference; TIA, transient ischemic attack; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; CHA₂DS₂-VASc, Congestive heart failure, Hypertension, Age over 75 years (doubled), Diabetes mellitus, Prior Stroke or TIA (doubled), Vascular disease, Age 65 to 74 years, Sex category; HAS-BLED, Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol; CMB, cerebral microbleed.

*As calculated using the Modification of Diet in Renal Disease formula.